Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer

Table 4 Comparison of clinicopathological features between high-ratio and low-ratio grades in both emergency surgery and bridge to surgery groups

Characteristic	ES group (n = 86)			BTS group (n = 38)
	dNLR ≥ 1.57	dNLR < 1.57	P-value	LMR ≥ 1.67	LMR < 1.67	P-value
Cross score, (%)			0.738			0.378
0	11 (27.5)	10 (21.7)		10 (50.0)	11 (61.1)
1	16 (40.0)	22 (47.8)		10 (50.0)	6 (33.3)
2	8 (20.0)	8 (17.4)		0 (0.0)	1 (5.6)
3	4 (10.0)	6 (13.0)
4	1 (2.5)	0 (0.0)
ASH (+)/(-), (%)	6 (15.0)/34 (85.0)	10 (21.7)/36 (78.3)		4 (20.0)/16 (80.0)	6 (33.3)/12 (66.7)
Comorbidities (+)/(-), (%)	20 (50.0)/20 (50.0)	17 (37.0)/29 (63.0)		9 (45.0)/11 (55.0)	12 (66.7/)/6 (33.3)
ASA grade, (%)			0.320			0.623
I	0 (0.0)	1 (1.6)		1 (5.0)	2 (11.1)
II	13 (56.5)	47 (74.6)		16 (80.0)	12 (66.7)
≥ III	10 (43.5)	15 (23.8)		3 (15.0)	4 (22.2)
Location, (%)			0.007			0.523
Right-side colon	2 (5.0)	11 (23.9)		1 (5.0)	0 (0.00)
Transverse colon	10 (25.0)	19 (41.3)		3 (15.0)	2 (11.1)
Left-side colon	21 (52.5)	13 (28.3)		13 (65.0)	15 (83.3)
Rectum	7 (17.5)	3 (6.5)		3 (15.0)	1 (5.6)
pTNM stage, (%)			0.141			0.592
I	0 (0.0)	4 (8.7)		-	-
II	12 (30.0)	10 (21.7)		4 (20.0)	5 (27.8)
III	17 (42.5)	24 (52.2)		13 (65.0)	12 (66.7)
IV	11 (27.5)	8 (17.4)		3 (15.0)	1 (5.6)
T stage, (%)			0.141			0.592
T1	0 (0.0)	4 (8.7)		-	-
T2	12 (30.0)	10 (21.7)		4 (20.0)	5 (27.8)
T3	17 (42.5)	24 (52.2)		13 (65.0)	12 (66.7)
T4	11 (27.5)	8 (17.4)		3 (15.0)	1 (5.6)
N stage, (%)			0.648			0.009
N0	16 (40.0)	14 (30.4)		4 (20.0)	5 (27.8)
N1	14 (35.0)	19 (41.3)		6 (30.0)	12 (66.7)
N2	10 (25.0)	13 (28.3)		10 (50.0)	1 (5.6)
M stage, (%)			0.260			0.552
M0	29 (72.5)	38 (82.6)		17 (85.0)	16 (88.9)
M1	11 (27.5)	8 (17.4)		3 (15.0)	2 (11.1)
Histological features, (%)			0.605			0.411
Well differentiated	1 (2.5)	2 (4.3)		-	-
Moderately differentiated	30 (75.0)	30 (65.2)		15 (75.0)	15 (83.3)
Poorly differentiated	9 (22.5)	14 (30.4)		5 (25.0)	3 (16.7)
LVI (+)/(-), (%)	9 (22.5)/31 (77.5)	6 (13.0)/40 (87.0)	0.249	10 (50.0)/10 (50.0)	4 (22.2)/14 (77.8)	0.076
Stoma construction, (%)			0.000			0.589
Stoma	17 (42.5)	3 (6.5)		4 (20.0)	4 (22.2)
None	23(57.5)	43 (93.5)		16 (80.0)	14 (77.8)
Pneumonia, (+)/(-), (%)	12 (30.0)/28 (70.0)	6 (13.0)/40 (87.0)	0.054	2 (10.0)/18(90.0)	6 (33.3)/12 (66.7)	0.086
Incision infection, (+)/(-), (%)	8 (20.0)/32 (80.0)	8 (17.4)/38 (82.6)	0.486	2 (10.0)/18 (90.0)	3 (16.7)/15 (83.3)	0.448
ICU intervention, (+)/(-), (%)	5 (12.5)/35 (87.5)	3 (6.5)/43 (93.5)	0.281	1 (5.0)/19 (95.0)	0 (0.0)/18 (100.0)	0.526
Leakage, (+)/(-), (%)	1 (2.5)/39 (97.5)	2 (4.3)/44 (95.7)	0.553	0 (0.0)/20 (100.0)	1 (5.6)/17 (94.4)	0.474
Sepsis, (+)/(-), (%)	1 (2.5)/39 (97.5)	2 (4.3)/44 (95.7)	0.553	0 (0.0)/20 (100.0)	1 (5.6)/17 (94.4)	0.474
SAE, (+)/(-), (%)	10 (25.0)/30 (75.0)	11 (23.9)/35 (76.1)	0.907	5 (25.0)/15 (75.0)	3 (16.7)/15 (83.3)	0.411
30-day mortality, n (%)	1 (2.5)/39 (97.5)	0 (0.0)/46 (100.0)	0.465	1 (5.0)/19 (95.0)	0 (0.0)/18 (100.0)	0.526
36-OS time, (months)	28.05 ± 10.28	31.61 ± 9.16	0.106	25.26 ± 13.88	33.78 ± 5.35	0.020
36-DFS time, (months)	23.10 ± 13.85	31.45 ± 9.35	0.009	22.67 ± 14.02	31.50 ± 8.89	0.046

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; Cross: Colorectal obstruction scoring system; ASH: Abdominal surgery history; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion; OS: Overall survival; DFS: Disease-free survival; ICU: Intense care unit; SAE: Severe adverse effects. P < 0.05 was considered statistically significant.